Sunrun Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sunrun Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $243.94M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $215.54M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | $204.60M | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | $194.50M | Feb 27, 2020 |
| FY2019 | Dec 31, 2018 | $240.12M | Feb 27, 2020 |
| FY2019 | Sep 30, 2018 | $204.96M | Feb 27, 2020 |
| FY2019 | Jun 30, 2018 | $170.54M | Feb 27, 2020 |
| FY2019 | Mar 31, 2018 | $144.36M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $152.27M | Mar 5, 2019 |
| FY2018 | Sep 30, 2017 | $144.55M | Mar 5, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.96B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.04B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.26B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $2.32B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.61B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $922.19M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $858.58M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $759.98M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $449.95M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($2.85B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($1.60B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $173.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($79.42M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($173.39M) | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | $12.50M | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | $28.99M | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | ($1.29M) | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | ($13.86M) | Feb 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($126.13M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($3.70B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($1.98B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($662.19M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($666.19M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($465.11M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($215.74M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | ($121.88M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($181.13M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($192.08M) | Mar 5, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.13M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $39.30M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $21.82M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $20.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $23.17M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $19.55M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $23.56M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $18.84M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $15.08M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $10.20M | Mar 5, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($421.44M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($766.15M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($820.74M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($848.79M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($817.19M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($317.97M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | ($204.49M) | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | ($62.46M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($96.10M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($200.14M) | Mar 5, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.57M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $20.96M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $18.20M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $8.58M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $3.10M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $25.35M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $4.95M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $7.96M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $12.54M | Mar 5, 2019 |
| FY2017 | Dec 31, 2015 | $13.03M | Mar 6, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.61B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $19.90B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $20.45B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $19.27B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $16.48B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $14.38B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $5.81B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.75B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $3.96B | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $3.57B | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.63B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.73B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $13.54B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.09B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $8.91B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $7.09B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $4.17B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.34B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.60B | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $2.51B | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.55B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.23B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.71B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $6.25B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $6.08B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $964.73M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $948.71M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $881.58M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $672.96M | Mar 6, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.12B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.28B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.28B | Feb 21, 2024 |
| FY2021 | Dec 31, 2020 | $4.28B | Feb 17, 2022 |
| FY2021 | Dec 31, 2019 | $95.09M | Feb 17, 2022 |
| FY2021 | Dec 31, 2018 | $87.54M | Feb 17, 2022 |
| FY2019 | Dec 31, 2017 | $87.54M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $87.54M | Mar 6, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.83B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($4.28B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.43B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $170.80M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($2.58M) | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $76.84M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $251.47M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $229.39M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $202.73M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $4.44M | Mar 6, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.70B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.90B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $10.67B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.40B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $6.50B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $4.80B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $2.25B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.75B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.29B | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $898.02M | Mar 6, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (12) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (7) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (12) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (7) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 22, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 27, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 27, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 233.61M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 225.66M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 219.39M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 214.18M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 208.18M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 201.41M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 118.45M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 113.15M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 104.32M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | 104.32M | Mar 6, 2018 |